NOMURA HOLDINGS INC-SPON ADR (NMR) Fundamental Analysis & Valuation

NYSE:NMR • US65535H2085

7.69 USD
-0.16 (-2.04%)
At close: Mar 6, 2026
7.8 USD
+0.11 (+1.43%)
After Hours: 3/6/2026, 8:04:00 PM

This NMR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall NMR gets a fundamental rating of 3 out of 10. We evaluated NMR against 241 industry peers in the Capital Markets industry. NMR has a bad profitability rating. Also its financial health evaluation is rather negative. NMR has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. NMR Profitability Analysis

1.1 Basic Checks

  • NMR had positive earnings in the past year.
  • NMR had a positive operating cash flow in the past year.
  • NMR had positive earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: NMR reported negative operating cash flow in multiple years.
NMR Yearly Net Income VS EBIT VS OCF VS FCFNMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500B -500B 1T -1T -1.5T

1.2 Ratios

  • NMR's Return On Assets of 0.61% is on the low side compared to the rest of the industry. NMR is outperformed by 69.75% of its industry peers.
  • NMR's Return On Equity of 10.62% is fine compared to the rest of the industry. NMR outperforms 61.76% of its industry peers.
  • With a Return On Invested Capital value of 0.68%, NMR is not doing good in the industry: 67.23% of the companies in the same industry are doing better.
  • NMR had an Average Return On Invested Capital over the past 3 years of 0.42%. This is significantly below the industry average of 7.26%.
  • The last Return On Invested Capital (0.68%) for NMR is above the 3 year average (0.42%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.61%
ROE 10.62%
ROIC 0.68%
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
NMR Yearly ROA, ROE, ROICNMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4 6 8

1.3 Margins

  • NMR has a Profit Margin of 8.05%. This is in the lower half of the industry: NMR underperforms 63.45% of its industry peers.
  • NMR's Profit Margin has declined in the last couple of years.
  • The Operating Margin of NMR (11.60%) is worse than 64.29% of its industry peers.
  • NMR's Operating Margin has declined in the last couple of years.
  • NMR has a Gross Margin (43.38%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of NMR has declined.
Industry RankSector Rank
OM 11.6%
PM (TTM) 8.05%
GM 43.38%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
NMR Yearly Profit, Operating, Gross MarginsNMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

1

2. NMR Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, NMR has less shares outstanding
  • NMR has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, NMR has an improved debt to assets ratio.
NMR Yearly Shares OutstandingNMR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
NMR Yearly Total Debt VS Total AssetsNMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10T 20T 30T 40T 50T

2.2 Solvency

  • Based on the Altman-Z score of -0.23, we must say that NMR is in the distress zone and has some risk of bankruptcy.
  • NMR's Altman-Z score of -0.23 is on the low side compared to the rest of the industry. NMR is outperformed by 81.09% of its industry peers.
  • NMR has a Debt/Equity ratio of 10.65. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of NMR (10.65) is worse than 88.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 10.65
Debt/FCF N/A
Altman-Z -0.23
ROIC/WACCN/A
WACCN/A
NMR Yearly LT Debt VS Equity VS FCFNMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5T 10T

2.3 Liquidity

  • A Current Ratio of 0.27 indicates that NMR may have some problems paying its short term obligations.
  • NMR has a worse Current ratio (0.27) than 82.77% of its industry peers.
  • A Quick Ratio of 0.27 indicates that NMR may have some problems paying its short term obligations.
  • NMR has a worse Quick ratio (0.27) than 82.77% of its industry peers.
Industry RankSector Rank
Current Ratio 0.27
Quick Ratio 0.27
NMR Yearly Current Assets VS Current LiabilitesNMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5T 10T 15T 20T 25T

3

3. NMR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 9.84% over the past year.
  • The Earnings Per Share has been growing by 10.96% on average over the past years. This is quite good.
  • Looking at the last year, NMR shows a decrease in Revenue. The Revenue has decreased by -4.21% in the last year.
  • Measured over the past years, NMR shows a quite strong growth in Revenue. The Revenue has been growing by 19.39% on average per year.
EPS 1Y (TTM)9.84%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-9.14%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%2.5%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.79% on average over the next years.
  • The Revenue is expected to decrease by -4.11% on average over the next years.
EPS Next Y10.55%
EPS Next 2Y3.07%
EPS Next 3Y3.79%
EPS Next 5YN/A
Revenue Next Year-15.08%
Revenue Next 2Y-7.01%
Revenue Next 3Y-4.11%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NMR Yearly Revenue VS EstimatesNMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1T 2T 3T 4T
NMR Yearly EPS VS EstimatesNMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 100

5

4. NMR Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 9.61 indicates a reasonable valuation of NMR.
  • Based on the Price/Earnings ratio, NMR is valued a bit cheaper than the industry average as 65.55% of the companies are valued more expensively.
  • NMR's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.29.
  • With a Price/Forward Earnings ratio of 9.65, the valuation of NMR can be described as very reasonable.
  • NMR's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NMR is cheaper than 70.17% of the companies in the same industry.
  • NMR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.57.
Industry RankSector Rank
PE 9.61
Fwd PE 9.65
NMR Price Earnings VS Forward Price EarningsNMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, NMR is valued a bit cheaper than 69.33% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 20.46
NMR Per share dataNMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • NMR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.91
PEG (5Y)0.88
EPS Next 2Y3.07%
EPS Next 3Y3.79%

6

5. NMR Dividend Analysis

5.1 Amount

  • NMR has a Yearly Dividend Yield of 4.13%, which is a nice return.
  • Compared to an average industry Dividend Yield of 6.46, NMR has a dividend in line with its industry peers.
  • NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 4.13%

5.2 History

  • The dividend of NMR is nicely growing with an annual growth rate of 15.59%!
  • NMR has paid a dividend for at least 10 years, which is a reliable track record.
  • The dividend of NMR decreased in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
NMR Yearly Dividends per shareNMR Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

5.3 Sustainability

  • 45.53% of the earnings are spent on dividend by NMR. This is a bit on the high side, but may be sustainable.
  • NMR's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP45.53%
EPS Next 2Y3.07%
EPS Next 3Y3.79%
NMR Yearly Income VS Free CF VS DividendNMR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500B -500B -1T -1.5T
NMR Dividend Payout.NMR Dividend Payout, showing the Payout Ratio.NMR Dividend Payout.PayoutRetained Earnings

NMR Fundamentals: All Metrics, Ratios and Statistics

NOMURA HOLDINGS INC-SPON ADR

NYSE:NMR (3/6/2026, 8:04:00 PM)

After market: 7.8 +0.11 (+1.43%)

7.69

-0.16 (-2.04%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)01-30
Earnings (Next)05-10
Inst Owners42.89%
Inst Owner Change9.13%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap22.56B
Revenue(TTM)4.63T
Net Income(TTM)370.05B
Analysts72.31
Price Target8.52 (10.79%)
Short Float %0.1%
Short Ratio1.92
Dividend
Industry RankSector Rank
Dividend Yield 4.13%
Yearly Dividend0.25
Dividend Growth(5Y)15.59%
DP45.53%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.87%
Min EPS beat(2)-4.65%
Max EPS beat(2)22.4%
EPS beat(4)2
Avg EPS beat(4)16.43%
Min EPS beat(4)-10.21%
Max EPS beat(4)58.19%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.5%
PT rev (3m)10.7%
EPS NQ rev (1m)-7.95%
EPS NQ rev (3m)29.28%
EPS NY rev (1m)0.73%
EPS NY rev (3m)4.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)3.78%
Revenue NY rev (3m)4.32%
Valuation
Industry RankSector Rank
PE 9.61
Fwd PE 9.65
P/S 0.77
P/FCF N/A
P/OCF 5.61
P/B 1.02
P/tB 1.04
EV/EBITDA 20.46
EPS(TTM)0.8
EY10.4%
EPS(NY)0.8
Fwd EY10.36%
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)1.37
OCFY17.82%
SpS9.94
BVpS7.54
TBVpS7.38
PEG (NY)0.91
PEG (5Y)0.88
Graham Number11.65
Profitability
Industry RankSector Rank
ROA 0.61%
ROE 10.62%
ROCE 1.68%
ROIC 0.68%
ROICexc 0.76%
ROICexgc 0.77%
OM 11.6%
PM (TTM) 8.05%
GM 43.38%
FCFM N/A
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
ROICexc(3y)0.46%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.09%
ROCE(5y)1.09%
ROICexgc growth 3Y16.87%
ROICexgc growth 5Y8.04%
ROICexc growth 3Y16.9%
ROICexc growth 5Y8.08%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score7
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 10.65
Debt/FCF N/A
Debt/EBITDA 62.4
Cap/Depr 1450.41%
Cap/Sales 19.46%
Interest Coverage 0.21
Cash Conversion 106.5%
Profit Quality N/A
Current Ratio 0.27
Quick Ratio 0.27
Altman-Z -0.23
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.84%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%-9.14%
EPS Next Y10.55%
EPS Next 2Y3.07%
EPS Next 3Y3.79%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%2.5%
Revenue Next Year-15.08%
Revenue Next 2Y-7.01%
Revenue Next 3Y-4.11%
Revenue Next 5YN/A
EBIT growth 1Y31.03%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year27047.4%
EBIT Next 3Y534.59%
EBIT Next 5YN/A
FCF growth 1Y58.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y236.88%
OCF growth 3YN/A
OCF growth 5YN/A

NOMURA HOLDINGS INC-SPON ADR / NMR FAQ

Can you provide the ChartMill fundamental rating for NOMURA HOLDINGS INC-SPON ADR?

ChartMill assigns a fundamental rating of 3 / 10 to NMR.


What is the valuation status of NOMURA HOLDINGS INC-SPON ADR (NMR) stock?

ChartMill assigns a valuation rating of 5 / 10 to NOMURA HOLDINGS INC-SPON ADR (NMR). This can be considered as Fairly Valued.


Can you provide the profitability details for NOMURA HOLDINGS INC-SPON ADR?

NOMURA HOLDINGS INC-SPON ADR (NMR) has a profitability rating of 3 / 10.


What is the financial health of NOMURA HOLDINGS INC-SPON ADR (NMR) stock?

The financial health rating of NOMURA HOLDINGS INC-SPON ADR (NMR) is 1 / 10.


What is the earnings growth outlook for NOMURA HOLDINGS INC-SPON ADR?

The Earnings per Share (EPS) of NOMURA HOLDINGS INC-SPON ADR (NMR) is expected to grow by 10.55% in the next year.